Last updated: February 28, 2026
What Is NDC 60429-0666?
NDC 60429-0666 corresponds to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody-drug conjugate approved by the FDA for relapsed/refractory multiple myeloma (RRMM). Approved on August 27, 2020, Blenrep is marketed by GlaxoSmithKline (GSK). It is indicated for adult patients who have received at least four prior therapies and are refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.
Market Size and Epidemiology
The multiple myeloma market is expanding due to rising incidence and therapeutic advancements.
| Parameter |
Data |
| Estimated annual new cases in the U.S. |
34,000 (American Cancer Society, 2022) |
| Prevalence of RRMM in diagnosed patients |
60-70% (National Cancer Institute, 2022) |
| Total U.S. multiple myeloma patients |
130,000 (Multiple Myeloma Research Foundation, 2022) |
The subset eligible for Blenrep (relapsed/refractory) is approximately 80,000 patients annually in the U.S. and similar figures in Europe, with incremental growth projected as survival improves.
Competitive Landscape
Key therapies include:
- Selinexor (Xpovio) – FDA-approved for RRMM; annual sales exceeding $250 million (IQVIA, 2022).
- Carfilzomib (Kyprolis) – Approved for RRMM; sales exceeding $600 million (IQVIA, 2022).
- Pomalidomide (Pomalyst) – Approved for RRMM; sales around $1.3 billion (IQVIA, 2022).
- Balversa and other antibody-drug conjugates are under investigation.
Blenrep entered a competitive market with high unmet demand, especially for patients refractory to multiple prior therapies.
Pricing Data and Cost Analysis
List Price:
- The wholesale acquisition cost (WAC) for Blenrep is approximately $7,700 per 20 mg vial.
- Dosage: 2.5 mg/kg every 3 weeks, with typical treatment cycles requiring 2-4 vials per dose depending on patient weight.
Estimated Treatment Cost:
| Parameter |
Value |
| Average patient weight |
70 kg |
| Dose per cycle |
175 mg (70 kg x 2.5 mg/kg) |
| Vials per cycle (20 mg each) |
9 vials (175 mg / 20 mg) |
| Cost per cycle |
$69,300 (9 x $7,700) |
| Treatment cycles (average) |
4 |
| Total cost per patient |
$277,200 |
Pricing models in the U.S. involve rebates, discounts, and negotiations, so actual net prices are typically 15-25% below WAC.
Revenue Projections and Market Entry Impact
Assuming:
- 80,000 eligible patients annually in the U.S.
- 20% market share initially, growing to 50% over five years.
- Average treatment cost per patient of $275,000.
- Penetration increases parallel to approval for additional indications, possibly expanding to Europe with a similar market share.
Initial Year Revenue Estimate:
- 16,000 patients (20% of eligible)
- Revenue = 16,000 x $275,000 = $4.4 billion (gross)
Five-Year Growth Assumption:
- Market share increases by 6% annually.
- Continued expansion in Europe and other territories.
Revenue projections suggest peak sales could reach $8-10 billion, considering potential combination approvals and indication expansions.
Price Trajectories
- Current WAC: ~$7,700 per vial.
- Price adjustments will follow inflation, competition, and payer negotiations.
- Expected to stabilize at a premium relative to similar antibody-drug conjugates, given its niche indication.
Regulatory and Policy Factors
Drug pricing in the U.S. remains influenced by Medicare/Medicaid policies, private payer negotiations, and value-based pricing initiatives. Europe and other markets adopt country-specific pricing regulations.
Risks and Market Uncertainties
- Competitive launches of similar therapies.
- Potential label expansion or restrictions.
- Cost-containment policies affecting reimbursement.
- Clinical trial outcomes for combination therapies.
Key Takeaways
- NDC 60429-0666 (Blenrep) is a monoclonal antibody-approved therapy for RRMM, with an estimated U.S. market size of approximately 80,000 eligible patients annually.
- List price stands at roughly $7,700 per vial, translating to treatment costs around $275,000 per patient.
- Market entry by Blenrep could generate peak revenues of $8-10 billion in the next five years, contingent on market penetration and indication expansion.
- Price stabilization and growth will depend on competitive dynamics, policy reforms, and the success of combination regimens.
FAQs
-
What is the primary indication for NDC 60429-0666?
Relapsed/refractory multiple myeloma in adult patients who have received at least four prior therapies.
-
How does the pricing of Blenrep compare to other RRMM therapies?
It is priced similarly to other antibody-drug conjugates and recent ADC developments, with a WAC of about $7,700 per vial.
-
What factors influence the future price of Blenrep?
Market competition, clinical trial outcomes, payer negotiations, and regulatory policies.
-
When could peak sales occur?
Within five years, assuming successful market penetration and indication expansion, peak sales could reach $10 billion.
-
Are there ongoing clinical trials that might impact Blenrep's market?
Yes, multiple combination trials and new indications could expand its market share and influence pricing strategies.
References
[1] American Cancer Society. (2022). Cancer facts & figures 2022.
[2] IQVIA. (2022). Medicine use and health outcomes report.
[3] National Cancer Institute. (2022). Multiple myeloma overview.
[4] Multiple Myeloma Research Foundation. (2022). Market and epidemiology data.
